May 17, 2026
Tracy Beth Hoeg, the FDA's acting drug center director, has been removed from her role after leading reviews of antidepressants, COVID-19 vaccines and RSV drugs. She is replaced by Dr. Mike Davis, as the agency continues a leadership shake-up.
Jun 26, 2026
Studies reveal context-dependent genetic effects in psychiatric disorders, reassuring evidence on prenatal antidepressant use, and findings on parental depression timing, diagnostic interview reliability, and rising self-diagnosis.
May 05, 2026
The United Arab Emirates has unveiled two gene therapy projects targeting autism, epilepsy, and rare brain disorders in children. The initiatives focus on underlying genetic causes and earlier diagnosis.
Mar 11, 2026
The FDA has approved leucovorin for cerebral folate deficiency with FOLR1 gene variant, not for autism broadly. Agency officials cited insufficient data for broader autism efficacy despite previous hype. Prescriptions for the drug surged 71% among children following earlier promotional statements.
Mar 18, 2026
Measles cases are reappearing across the United States, challenging health systems unprepared for a disease declared eliminated in 2000. Clinical leaders must ensure rapid identification, isolation protocols, and vaccination strategies to prevent outbreaks.
Feb 13, 2026
A study of 434 toddlers found no association between maternal mRNA COVID-19 vaccination during or shortly before pregnancy and autism or other neurodevelopmental disorders in offspring aged 18-30 months.